Fueling the revolution: RIBOTACs manipulating RNA decay.

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-09-13 DOI:10.1016/j.trecan.2025.08.011

Wei Zhou, Jinmei Jin, Hongzhuan Chen, Weidong Zhang, Xin Luan

引用次数: 0

Abstract

Ribonuclease-targeting chimeras (RIBOTACs) are innovative RNA-targeting molecules that combine small-molecule RNA binders with endogenous RNase L-recruiting moieties, enabling catalytic degradation of previously considered 'undruggable' transcripts. The unique mechanism of RIBOTACs allows them to circumvent limitations of existing RNA-targeted therapeutics, expanding their therapeutic potential in oncology.

查看原文本刊更多论文

推动革命：RIBOTACs操纵RNA衰变。

核糖核酸酶靶向嵌合体（RIBOTACs）是一种创新的RNA靶向分子，它将小分子RNA结合物与内源性RNA酶l-招募片段结合，能够催化降解以前认为“不可药物”的转录物。RIBOTACs的独特机制使其能够规避现有rna靶向治疗的局限性，扩大其在肿瘤学中的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.